Celularity Inc
NASDAQ:CELU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
ChinaEtek Service & Technology Co Ltd
SZSE:301208
|
CN |
|
Shenzhen SDG Service Co Ltd
SZSE:300917
|
CN |
|
C
|
Cowell e Holdings Inc
HKEX:1415
|
CN |
|
Heritage Foods Ltd
NSE:HERITGFOOD
|
IN |
Celularity Inc
Other Equity
Celularity Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celularity Inc
NASDAQ:CELU
|
Other Equity
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$1.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$31m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
$8.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
-$49.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$77.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
Celularity Inc
Glance View
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
See Also
What is Celularity Inc's Other Equity?
Other Equity
0
USD
Based on the financial report for Sep 30, 2025, Celularity Inc's Other Equity amounts to 0 USD.
